A phase Ib, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, pharmacokinetics and pharmacodynamics of selnoflast in participants with moderate to severe asthma
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Selnoflast (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms Asthma Study
- Sponsors Roche
- 30 Sep 2024 Status changed to completed.
- 04 Jan 2024 Status changed from not yet recruiting to recruiting.
- 25 Sep 2023 New trial record